Revision 1

Erlotinib	Cell Signaling	
Store	Orders: 877-616-CELL (2355) orders@cellsignal.com	
10 mg	Support: 877-678-TECH (8324)	
#5083	Web: info@cellsignal.com cellsignal.com	
#2	3 Trask Lane Danvers Massachusetts 01923 USA	
For Research Use Only. Not for Use in Diagnostic Procedures.		
Background	Erlotinib is a novel and potent ATP-competitive inhibitor of the EGFR kinase pathway. It inhibited EGFR	

Background	Erlotinib is a novel and potent ATP-competitive inhibitor of the EGFR kinase pathway. It inhibited EGFR autophosphorylation with an IC_{50} of 20 nM <i>in vitro</i> and inhibit purified EGFR kinase with an IC_{50} of 2 nM (1). Erlotonib is greater than 1000-fold more selective for EGFR than c-src and v-abl (1), ErbB-2, and ErbB-4 (2). Studies have shown that erlotinib inhibits growth and induces G1 cell cycle arrest in multiple cell types, many of which overexpress EGFR (1,3-5).
	This product has applications to SARS-CoV-2 research into the mechanisms of the Novel Coronavirus, which has caused the COVID-19 pandemic.
Molecular Formula	C ₂₂ H ₂₃ N ₃ O ₄
Molecular Weight	393.44 g/mol
Purity	>99%
CAS	183321-74-6
Solubility	Soluble in DMSO at 100mg/ml and EtOH at 10mg/ml.
Storage	Store lyophilized or in solution at -20°C, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Directions for Use	Erlotinib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 10 mg in 2.54 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pretreatment at 0.1-10 μ M for 0.5-2 hours prior to treating with a stimulator. It can also be used alone, with varying treatment times lasting up to 24 hours. Soluble in DMSO at 100 mg/ml, soluble in ethanol at 10 mg/ml with warming; very poorly soluble in water with a maximum solubility ~5-20 μ M.
Background References	1. Moyer, J.D. et al. (1997) <i>Cancer Res</i> 57, 4838-48. 2. Wood, E.R. et al. (2004) <i>Cancer Res</i> 64, 6652-9. 3. Huether, A. et al. (2005) <i>J Hepatol</i> 43, 661-9. 4. Ling, Y.H. et al. (2007) <i>Mol Pharmacol</i> 72, 248-58. 5. Yamasaki, F. et al. (2007) <i>Mol Cancer Ther</i> 6, 2168-77.
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise

attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.